PHARMACOLOGY

药理学核心机构开展临床药理学、生化相关研究， 药物遗传学研究，旨在改善癌症患者的生活质量和结果。 该设施对于分析方法的开发、验证和实施至关重要， 评估药代动力学或药效学的影响，并用于测量生化相关性 优化给药时间表的必要性。一些新的抗癌疗法需要 根据生化终点和药理学核心确定最佳剂量， 用于确定生物调节剂量。该设施提供DMA和RNA分离， 药物遗传学研究。该设施的科学主任是M。Eileen Dolan博士和 技术总监是Jacqueline Ramirez，MS（分析组件）和Shannon Delaney （生化成分）。Dolan博士在生化酶测定、药物分析和生物技术方面具有丰富的经验。 代谢和抗癌剂的药代动力学/药效学研究。拉米雷斯女士和 Delaney负责质量控制，分析方法开发，分析维护， 设备和编写报告。该设施提供分析和生物化学服务， 大学内的调查人员（UCCRC的成员和非成员），以及 其他癌症中心的研究人员。此外，Dolan博士还提供学习咨询服务。 和分析设计。

The Pharmacology Core Facility conducts clinical pharmacology, biochemical correlates, and pharmacogenetic studies with the aim of improving the quality of life and outcome for cancer patients. The Facility is essential for the development, validation, and implementation of analytical methods to assess the effect of pharmacokinetics or pharmacodynamics, and for measuring biochemical correlates necessary to optimize drug administration schedules. Some novel anticancer therapies require determination of the optimal dose based on a biochemical endpoint and the Pharmacology Core is equipped to define the bio-modulatory dose. The Facility offers DMA and RNA isolation for pharmacogenetic studies. The Scientific Director of the Facility is M. Eileen Dolan, PhD, and the Technical Directors are Jacqueline Ramirez, MS (Analytical Component) and Shannon Delaney (Biochemical Component). Dr. Dolan has extensive experience in biochemical enzyme assays, drug metabolism, and pharmacokinetic/pharmacodynamic studies of anticancer agents. Ms. Ramirez and Delaney are responsible for quality control, analytical method development, maintenance of analytical equipment, and preparation of reports. The Facility renders analytical and biochemical services to investigators within the University (both members and non-members of the UCCRC), as well as investigators at other Cancer Centers. In addition, Dr. Dolan provides consultative services on study and assay design.